Phase-II trial of tamoxifen in advanced breast cancer

Roy Glen Wiggans, P. V. Woolley, Tarilyn Smythe, D. Hoth, J. S. Macdonald, Linda Green, P. S. Schein

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Seventy-eight advanced breast cancer patients, most of whom had had prior treatment, were treated with the synthetic antiestogen tamoxifen. The overall objective response rate was 27% (21/78). An additional 19% (15/78) showed disease stabilization. Sixty-seven percent (14/21) of the responses were in soft tissue sites, 24% (5/21) on bony sites and one each occurred in liver and nodular lung disease. Forty percent of patients with soft-tissue disease alone responded, while 10% of patients with visceral disease showed responses in visceral sites. The response rate was 28% among patients with a known positive estrogen receptor (ER) assay. It was 21% among patients who had previously received cytotoxic drugs. Toxicity was mild and was seen in nausea and vomiting, hot flushes and vaginal bleeding, and occasional myelosuppression. One patient was withdrawn from the study because of a rash. In two patients the disease flared, once with concomitant hypercalcemia. Tamoxifen is a useful agent for advanced breast cancer even in some patients with visceral disease.

Original languageEnglish (US)
Pages (from-to)45-48
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume3
Issue number1
DOIs
StatePublished - Jan 1 1979

Fingerprint

Tamoxifen
Breast Neoplasms
Tissue
Pulmonary diseases
Estrogen Receptors
Liver
Toxicity
Assays
Stabilization
Uterine Hemorrhage
Hypercalcemia
Exanthema
Nausea
Lung Diseases
Vomiting
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Wiggans, R. G., Woolley, P. V., Smythe, T., Hoth, D., Macdonald, J. S., Green, L., & Schein, P. S. (1979). Phase-II trial of tamoxifen in advanced breast cancer. Cancer Chemotherapy and Pharmacology, 3(1), 45-48. https://doi.org/10.1007/BF00254419

Phase-II trial of tamoxifen in advanced breast cancer. / Wiggans, Roy Glen; Woolley, P. V.; Smythe, Tarilyn; Hoth, D.; Macdonald, J. S.; Green, Linda; Schein, P. S.

In: Cancer Chemotherapy and Pharmacology, Vol. 3, No. 1, 01.01.1979, p. 45-48.

Research output: Contribution to journalArticle

Wiggans, RG, Woolley, PV, Smythe, T, Hoth, D, Macdonald, JS, Green, L & Schein, PS 1979, 'Phase-II trial of tamoxifen in advanced breast cancer', Cancer Chemotherapy and Pharmacology, vol. 3, no. 1, pp. 45-48. https://doi.org/10.1007/BF00254419
Wiggans RG, Woolley PV, Smythe T, Hoth D, Macdonald JS, Green L et al. Phase-II trial of tamoxifen in advanced breast cancer. Cancer Chemotherapy and Pharmacology. 1979 Jan 1;3(1):45-48. https://doi.org/10.1007/BF00254419
Wiggans, Roy Glen ; Woolley, P. V. ; Smythe, Tarilyn ; Hoth, D. ; Macdonald, J. S. ; Green, Linda ; Schein, P. S. / Phase-II trial of tamoxifen in advanced breast cancer. In: Cancer Chemotherapy and Pharmacology. 1979 ; Vol. 3, No. 1. pp. 45-48.
@article{08229f301fef4d1b9cbaa47a6d435ddf,
title = "Phase-II trial of tamoxifen in advanced breast cancer",
abstract = "Seventy-eight advanced breast cancer patients, most of whom had had prior treatment, were treated with the synthetic antiestogen tamoxifen. The overall objective response rate was 27{\%} (21/78). An additional 19{\%} (15/78) showed disease stabilization. Sixty-seven percent (14/21) of the responses were in soft tissue sites, 24{\%} (5/21) on bony sites and one each occurred in liver and nodular lung disease. Forty percent of patients with soft-tissue disease alone responded, while 10{\%} of patients with visceral disease showed responses in visceral sites. The response rate was 28{\%} among patients with a known positive estrogen receptor (ER) assay. It was 21{\%} among patients who had previously received cytotoxic drugs. Toxicity was mild and was seen in nausea and vomiting, hot flushes and vaginal bleeding, and occasional myelosuppression. One patient was withdrawn from the study because of a rash. In two patients the disease flared, once with concomitant hypercalcemia. Tamoxifen is a useful agent for advanced breast cancer even in some patients with visceral disease.",
author = "Wiggans, {Roy Glen} and Woolley, {P. V.} and Tarilyn Smythe and D. Hoth and Macdonald, {J. S.} and Linda Green and Schein, {P. S.}",
year = "1979",
month = "1",
day = "1",
doi = "10.1007/BF00254419",
language = "English (US)",
volume = "3",
pages = "45--48",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Phase-II trial of tamoxifen in advanced breast cancer

AU - Wiggans, Roy Glen

AU - Woolley, P. V.

AU - Smythe, Tarilyn

AU - Hoth, D.

AU - Macdonald, J. S.

AU - Green, Linda

AU - Schein, P. S.

PY - 1979/1/1

Y1 - 1979/1/1

N2 - Seventy-eight advanced breast cancer patients, most of whom had had prior treatment, were treated with the synthetic antiestogen tamoxifen. The overall objective response rate was 27% (21/78). An additional 19% (15/78) showed disease stabilization. Sixty-seven percent (14/21) of the responses were in soft tissue sites, 24% (5/21) on bony sites and one each occurred in liver and nodular lung disease. Forty percent of patients with soft-tissue disease alone responded, while 10% of patients with visceral disease showed responses in visceral sites. The response rate was 28% among patients with a known positive estrogen receptor (ER) assay. It was 21% among patients who had previously received cytotoxic drugs. Toxicity was mild and was seen in nausea and vomiting, hot flushes and vaginal bleeding, and occasional myelosuppression. One patient was withdrawn from the study because of a rash. In two patients the disease flared, once with concomitant hypercalcemia. Tamoxifen is a useful agent for advanced breast cancer even in some patients with visceral disease.

AB - Seventy-eight advanced breast cancer patients, most of whom had had prior treatment, were treated with the synthetic antiestogen tamoxifen. The overall objective response rate was 27% (21/78). An additional 19% (15/78) showed disease stabilization. Sixty-seven percent (14/21) of the responses were in soft tissue sites, 24% (5/21) on bony sites and one each occurred in liver and nodular lung disease. Forty percent of patients with soft-tissue disease alone responded, while 10% of patients with visceral disease showed responses in visceral sites. The response rate was 28% among patients with a known positive estrogen receptor (ER) assay. It was 21% among patients who had previously received cytotoxic drugs. Toxicity was mild and was seen in nausea and vomiting, hot flushes and vaginal bleeding, and occasional myelosuppression. One patient was withdrawn from the study because of a rash. In two patients the disease flared, once with concomitant hypercalcemia. Tamoxifen is a useful agent for advanced breast cancer even in some patients with visceral disease.

UR - http://www.scopus.com/inward/record.url?scp=0018584228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018584228&partnerID=8YFLogxK

U2 - 10.1007/BF00254419

DO - 10.1007/BF00254419

M3 - Article

C2 - 535127

AN - SCOPUS:0018584228

VL - 3

SP - 45

EP - 48

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -